Volume 4

ABCC8 clinical and functional characterization of the Pro1198Leu ABCC8 gene mutation associated with permanent neonatal diabetes mellitus, Takagi 269–273 adipocyte fatty acid binding protein obesity as the common soil of non-alcoholic fatty liver disease and diabetes: role of adipokines (Review Article), Hui 413–425 adipokines glypican-4 is a new comer of adipokines working as insulin sensitizer, Tamori 250–251 adiponectin obesity as the common soil of non-alcoholic fatty liver disease and diabetes: role of adipokines (Review Article), Hui 413–425 serum adiponectin levels predict the risk of coronary heart disease in Japanese patients with type 2 diabetes, Obata 475–482 adverse drug reaction three ileus cases associated with the use of DPP-4 inhibitors in diabetic patients (Case Report), Kanasaki 676 albuminuria comparison of effects of cilnidipine and azelnidipine on blood pressure, heart rate and albuminuria in type 2 diabetics with hypertension: a pilot study, Abe 202–205 comparison of spironolactone and trichlormethiazide as add-on therapy to renin–angiotensin blockade for reduction of albuminuria in diabetic patients, Hase 316–319 aldosterone blockers comparison of spironolactone and trichlormethiazide as add-on therapy to renin–angiotensin blockade for reduction of albuminuria in diabetic patients, Hase 316–319 Alzheimer’s disease insulin resistance in the brain: a new therapeutic target for Alzheimer’s disease (Commentary), Umegaki 150–151 new therapeutic strategy for Alzheimer’s disease using antidiabetes agents (Commentary), Yokono 152–153 angiotensin-converting enzyme gene angiotensin-converting enzyme gene variants interact with the renin–angiotensin system pathway to confer risk and protection against type 2 diabetic retinopathy (Letter to the Editor), Singh Cheema 103–104 angiotensin-converting enzyme inhibitor combination therapy with an angiotensin-convertingenzyme inhibitor and an angiotensin II receptor antagonist ameliorates microinflammation and oxidative stress in patients with diabetic nephropathy, Nakamura 195–201 angiotensin receptor blocker combination therapy with an angiotensin-convertingenzyme inhibitor and an angiotensin II receptor antagonist ameliorates microinflammation and oxidative stress in patients with diabetic nephropathy, Nakamura 195–201 anthropometric indicators anthropometric indicators of obesity for identifying cardiometabolic risk factors in a rural Bangladeshi population, Bhowmik 361–368 anti-cancer ascorbic acid therapy pseudohypoglycemia or hyperglycemia caused by interference with self-monitoring blood glucose measurements in anti-cancer ascorbic acid therapy (Letter to the Editor), Kimura 682 antidiabetic agents new therapeutic strategy for Alzheimer’s disease using antidiabetes agents (Commentary), Yokono 152–153 antioxidant mechanism-based antioxidant therapies promise to prevent diabetic complications (Editorial), Nishikawa 105–107 arterial stiffness increased arterial stiffness is closely associated with hyperglycemia and improved by glycemic control in diabetic patients, Ibata 82–87 Asian changing characteristics of the type 2 diabetes epidemic in China and other Asian countries, Yang 223–224 efficacy and safety of exenatide once-weekly vs exenatide twice-daily in Asian patients with type 2 diabetes mellitus, Ji 53–61 insulin degludec compared with insulin glargine in insulin-na€ıve patients with type 2 diabetes: a 26-week, randomized, controlled, Pan-Asian, treat-to-target trial, Onishi 605 atherosclerosis extension of the mitochondria dysfunction hypothesis of metabolic syndrome to atherosclerosis with emphasis on the endocrine-disrupting chemicals and biophysical laws (Review Article), Lee 19–33 atorvastatin comparison of effects of pitavastatin and atorvastatin on glucose metabolism in type 2 diabetic patients with hypercholesterolemia, Mita 297–303 effects of patient-tailored atorvastatin therapy on ameliorating the levels of atherogenic lipids and inflammation beyond lowering low-density lipoprotein cholesterol in patients with type 2 diabetes, Son 466–474 azelnidipine comparison of effects of cilnidipine and azelnidipine on blood pressure, heart rate and albuminuria in type 2 diabetics with hypertension: a pilot study, Abe 202–205